Free tool
FAERS Monitor: Empaveli
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215014 or its brand name (Empaveli, Pegcetacoplan). Reports on generic versions are filed under their own applications.
Reports
1,188
Serious
796
67% of reports
Hospitalization
329
Death reported
92
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue157
- off label use142
- haemoglobin decreased128
- haemolysis109
- breakthrough haemolysis96
- headache75
- drug ineffective67
- product dose omission issue62
- covid-1957
- diarrhoea57
- pyrexia56
- platelet count decreased54
- injection site pain53
- condition aggravated52
- malaise52
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 22 |
| 2022 | 56 |
| 2023 | 110 |
| 2024 | 540 |
| 2025 | 218 |
| 2026 | 242 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,971 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breakthrough haemolysisSignal | 96 | 5614.7 | 4495.1 | 404,933 |
| haemolysisSignal | 109 | 253.5 | 211.6 | 26,785 |
| haemoglobin decreasedSignal | 128 | 22.1 | 18.8 | 2,566 |
| platelet count decreasedSignal | 54 | 9.0 | 6.9 | 376 |
| covid-19Signal | 57 | 5.8 | 4.5 | 221 |
| product dose omission issueSignal | 62 | 3.7 | 2.9 | 123 |
| fatigueSignal | 157 | 3.6 | 3.1 | 299 |
| injection site painSignal | 53 | 3.1 | 2.4 | 72 |
| condition aggravatedSignal | 52 | 3.0 | 2.3 | 70 |
| off label useSignal | 142 | 2.9 | 2.5 | 179 |
| pyrexiaSignal | 56 | 2.9 | 2.2 | 67 |
| headacheSignal | 75 | 2.1 | 1.7 | 44 |
| malaiseSignal | 52 | 2.1 | 1.6 | 29 |
| diarrhoea | 57 | 1.6 | 1.2 | 11 |
| drug ineffective | 67 | 0.9 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.